Dabigatran etexilate: the first oral anticoagulant available in the United States since warfarin.

@article{Tran2011DabigatranET,
  title={Dabigatran etexilate: the first oral anticoagulant available in the United States since warfarin.},
  author={Arlene Tran and Angela Cheng-Lai},
  journal={Cardiology in review},
  year={2011},
  volume={19 3},
  pages={
          154-61
        }
}

• Arlene Tran, Angela Cheng-Lai
• Published in Cardiology in review 2011
• DOI:10.1097/CRD.0b013e3182137758

For more than 5 decades, warfarin has been the mainstay of therapy when oral anticoagulation is required. It has been shown to be effective in the prevention as well as treatment of various thromboembolic disorders. However, drawbacks of warfarin, such as time-consuming requirements for frequent international normalized ratio monitoring, as well as drug and food interactions, have encouraged the development of alternative oral agents. One such agent, dabigatran, has risen up to the challenge… CONTINUE READING

Save to Library

Create Alert

Cite

View on PubMed